Table 4.

Final version of the items and results for the restaging section of the CT report

Statement	Information to be included in the report	Agreement (median)	Consensus (IQR)	Stability (p)
Clinical referrals	- Possible extraparietal extension of the primary lesion at laparoscopy, if performed; site (upper/middle/ lower 1/3, lesser/greater curvature, anterior /posterior wall); - Specify the date of the CT examination used for the comparison. The radiologist should point out in the radiological report if clinical information provided is not adequate.	9	1	/
Technique	- Specify if correct gastric distension has been performed, the modality of distension (air or water), and the reasons for any failure to distension; -Specify if gastric hypotonization has been carried out; - Report any adverse reaction (in that case, report the contrast agent administered); - Report the presence of any motion artifacts or problems that occurred during CT examination; - Report if dual-energy technique (DECT) was used.	9	0	0.257
Findings
T parameter	- Site (upper/middle/lower 1/3, lesser/greater curvature, anterior/posterior wall); - Report the lesion D-max specifying the percentage reduction compared to the staging CT); - Gastric wall infiltration ( ≤ T2 or ≥ T3) and if there have been any changes compared with the staging CT (downstaging/upstaging); - Distance from the esophago-gastric junction or possible esophageal infiltration (the involvement of the esophagus should be expressed in mm from the hiatus); - Possible infiltration of perigastric organs/structures (pancreas, liver, mesocolon ...); - Possible duodenal infiltration; - Features of the lesion (stenosing, ulcerated, perforated);	9	0	0.465
N parameter	- Specify if N0 or N+; - If N+ specify the short axis of the largest metastatic LN for each station (or any confluent LNs) compared with the previous one (e.g., st.6: 6 mm ex 10 mm); - Site of metastatic LN (stations number according to JGCA or anatomical description according to AJCC) - Possible adhesion/infiltration of anatomical structures.	9	0,5	0,046
Peritoneal carcinomatosis	- Appearance/disappearance or increase/reduction of ascites, also to suggest paracentesis; - Appearance/disappearance or increase/reduction of peritoneal carcinomatosis; - Specify if supra- or sub-mesocolic infiltration; - Specify involvement of bowel loops and mesentery (especially mesenteric root infiltration). - Absence/presence of omental cake	9	0	0.564
Liver metastases	- Specify presence/absence of liver metastases; - Number: report the increase/stability or reduction in the number of liver metastases; specify if unique, or number up to 3, or if > 3 indicate “multiple”; - Site (liver segments involved); - Dimension: indicate increase/stability or reduction of liver dimensional metastases, reporting the maximum diameter (single measurement in mm) of largest lesions (up to 2), chosen as a target in the staging report, also getting the measures of comparison with the previous one (e.g., mts. 1: 5 ex 10 mm; mts. 2: 3 ex 8 mm) or maximum diameter of max 2 larger metastases identified in the restaging CT, always reporting comparison with the previous one, if the targets have not been previously identified. - Specify whether contact/infiltration of a large intrahepatic vessel (portal vein, IVC, supra-hepatic veins), also reporting the comparison with the staging CT;	9	0	0.705
Other metastases	- Specify whether disease progression/stability or response to therapy; - Site (lung, bone ...); - Number: report the increase/stability or reduction in number for each site; specify if unique, or number up to max 3, or if > 3 indicate “multiple”; - Dimension: indicate increase/stability or reduction of dimensional metastases for each site, reporting the maximum diameter (single measure in mm) of the metastasis/es chosen as a target in the staging report (up to 2 per organ in accordance with RECIST 1.1), getting the comparison with the previous one (eg. mts1: 5 ex 10 mm; mts2: 3 ex 8 mm) or maximum diameter of max 2 larger metastases identified in the restaging CT, always reporting comparison with the previous one (e.g. mts1: 5 ex 10 mm; mts2: 3 ex 8 mm), if the targets are not previously identified. - Specify if there are non-measurable lesions (lymphangitis, pleural effusion ...);	9	0	0.084
Useful information for the surgeon	- Vascular anomalies; - Presence of incisional hernias.	9	1	0.162
Conclusions/advice	- The radiologist should provide post-treatment clinical-radiological staging (ycTNM [25] (CT): T expressed as ≤ T2 or ≥ T3, N expressed as N0 or N +, M expressed as M0 or M +) - The radiologist should recommend the discussion of the clinical case at the multidisciplinary group.	8	2	0.464